More Web Proxy on the site http://driver.im/

Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). (Q38185304)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2014

Language	Label	Description	Also known as
English	Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).	scientific article published on June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Christos Vaklavas

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Andres Forero

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

publication date

1 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

253-263

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Antibody Conjugate Therapeutics: Challenges and Potential

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin promotes breast cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, l-amino acid-defined diet, accelerates motility of hepatoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Identifying potential tumor markers and antigens by database mining and rapid expression screening

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Construction of engineered CHO strains for high-level production of recombinant proteins

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

DC-HIL is a negative regulator of T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Identifiers

10.1007/S40259-014-0085-2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38185304&oldid=2201378210"